TP53 and cancer: Although determining TP53 status, unlike KRAS status, was not recommended by the NCCN as a prognostic predictor, the high frequency of TP53 mutations observed in many sequenced cancers highlight the important role of TP53 in the inhibition of cancer development [62, 63].